January 2021 Publications
- MAIT cell-directed therapy of Mycobacterium tuberculosis infection. Sakai S, Kauffman KD, Oh S, Nelson CE, Barry CE 3rd, Barber DL. Mucosal Immunol. 2021 Jan. doi: 10.1038/s41385-020-0332-4. Epub 2020 Aug 18.
- Clinical features of tuberculosis and Bacillus Calmette-Guerin (BCG) -associated adverse effects in children: A 12-year study. Yang TL, Lee CM, Lee KL, Yen TY, Lu CY, Lee PI, Chen CM, Huang LM, Chang LY. J Formos Med Assoc. 2021 Jan. doi: 10.1016/j.jfma.2020.06.012. Epub 2020 Jun 15.
- Cell Envelope Proteomics of Mycobacteria. Hermann C, Karamchand L, Blackburn JM, Soares NC. J Proteome Res. 2021 Jan 1. doi: 10.1021/acs.jproteome.0c00650. Epub 2020 Nov 3.
- MTBVAC vaccination protects rhesus macaques against aerosol challenge with M. tuberculosis and induces immune signatures analogous to those observed in clinical studies.White AD, Sibley L, Sarfas C, Morrison A, Gullick J, Clark S, Gleeson F, McIntyre A, Arlehamn CL, Sette A, Salguero FJ, Rayner E, Rodriguez E, Puentes E, Laddy D, Williams A, Dennis M, Martin C, Sharpe S. NPJ Vaccines. 2021 Jan 4. doi: 10.1038/s41541-020-00262-8.
- A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates. Tanner R, White AD, Boot C, Sombroek CC, O’Shea MK, Wright D, Hoogkamer E, Bitencourt J, Harris SA, Sarfas C, Wittenberg R, Satti I, Fletcher HA, Verreck FAW, Sharpe SA, McShane H. NPJ Vaccines. 2021 Jan 4. doi: 10.1038/s41541-020-00263-7.
- Composition and Clinical Significance of Exosomes in Tuberculosis: A Systematic Literature Review. Biadglegne F, König B, Rodloff AC, Dorhoi A, Sack U. J Clin Med. 2021 Jan 4. doi: 10.3390/jcm10010145.
- Developing New Anti-Tuberculosis Vaccines: Focus on Adjuvants. Franco AR, Peri F. Cells. 2021 Jan 5. doi: 10.3390/cells10010078.
- Identification of CTL Epitopes on Efflux Pumps of the ATP-Binding Cassette and the Major Facilitator Superfamily of Mycobacterium tuberculosis.Lin Y, Dong Y, Gao Y, Shi R, Li Y, Zhou X, Liu W, Li G, Qi Y, Wu Y. J Immunol Res. 2021 Jan 5. doi: 10.1155/2021/8899674. eCollection 2021.
- Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins. Mustafa AS. Vaccines (Basel). 2021 Jan 7. doi: 10.3390/vaccines9010027.
- Design of Trehalose-based Amide/Sulfonamide C-type Lectin Receptor Ligands. Ryter KT, Rasheed OK, Buhl C, Evans JT. ChemMedChem. 2021 Jan 7. doi: 10.1002/cmdc.202000775. Online ahead of print.
- Preclinical evaluation of tuberculosis vaccine candidates: Is it time to harmonize study design and readouts for prioritizing their development? Flores-Valdez MA, Segura-Cerda CA. Vaccine. 2021 Jan 8. doi: 10.1016/j.vaccine.2020.11.073. Epub 2020 Dec 14.
- Predicted Structural Variability of Mycobacterium tuberculosis PPE18 Protein With Immunological Implications Among Clinical Strains.Hakim JMC, Yang Z. Front Microbiol. 2021 Jan 8. doi: 10.3389/fmicb.2020.595312. eCollection 2020.
- Ultra-low Dose Aerosol Infection of Mice with Mycobacterium tuberculosis More Closely Models Human Tuberculosis.Plumlee CR, Duffy FJ, Gern BH, Delahaye JL, Cohen SB, Stoltzfus CR, Rustad TR, Hansen SG, Axthelm MK, Picker LJ, Aitchison JD, Sherman DR, Ganusov VV, Gerner MY, Zak DE, Urdahl KB. Cell Host Microbe. 2021 Jan 13. doi: 10.1016/j.chom.2020.10.003. Epub 2020 Nov 2.
- In silico analysis of epitope-based vaccine candidate against tuberculosis using reverse vaccinology. Bibi S, Ullah I, Zhu B, Adnan M, Liaqat R, Kong WB, Niu S.Sci Rep. 2021 Jan 13. doi: 10.1038/s41598-020-80899-6.
- Intranasal Immunization with Peptide-based Immunogenic Complex Enhances BCG Vaccine Efficacy in murine model of Tuberculosis. Kumar S, Bhaskar A, Patnaik G, Sharma C, Singh DK, Kaushik S, Chaturvedi S, Das G, Dwivedi VP. JCI Insight. 2021 Jan 14. doi: 10.1172/jci.insight.145228. Online ahead of print.
- PE_PGRS33, an Important Virulence Factor of Mycobacterium tuberculosis and Potential Target of Host Humoral Immune Response. Kramarska E, Squeglia F, De Maio F, Delogu G, Berisio R. Cells. 2021 Jan 15. doi: 10.3390/cells10010161.
- Proteomic characterization of a second-generation version of the BCGdeltaBCG1419c vaccine candidate by means of electrospray-ionization quadrupole time-of-flight mass spectrometry. Velázquez-Fernández JB, Ferreira-Souza GHM, Rodríguez-Campos J, Aceves-Sánchez MJ, Bravo-Madrigal J, Vallejo-Cardona AA, Flores-Valdez MA.Pathog Dis. 2021 Jan 16. doi: 10.1093/femspd/ftaa070.
- Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine.Fu H, Lewnard JA, Frost I, Laxminarayan R, Arinaminpathy N. Nat Commun. 2021 Jan 18. doi: 10.1038/s41467-020-20731-x.
- Stronger induction of trained immunity by mucosal BCG or MTBVAC vaccination compared to standard intradermal vaccination. Vierboom, MPM, Dijkman K, Sombroek CC, Hofman SO, Boot C, Vervenne RAW, Haanstra KG, van der Sande M, van Emst L, Dominguez-Andres J, Moorlag SJCFM, Kocken CHM, Thole J, Rodriguez E, Puentes E, Martens JHA, van Crevel R, Netea MG, Aguilo N, Marin C, Verreck FAW. Cell Rep Med. 2021 Jan 19. doi: 10.1016/j.xcrm.2020.100185
- Sterilization by Adaptive Immunity of a Conditionally Persistent Mutant of Mycobacterium tuberculosis. Vilchèze C, Porcelli SA, Chan J, Jacobs WR Jr.mBio. 2021 Jan 19. doi: 10.1128/mBio.02391-20.
- A structured Markov chain model to investigate the effects of pre-exposure vaccines in tuberculosis control.Fernández-Peralta R, Gómez-Corral A. J Theor Biol. 2021 Jan 21. doi: 10.1016/j.jtbi.2020.110490. Epub 2020 Sep 16.
- Perspectives and Advances in the Understanding of Tuberculosis. Kinsella RL, Zhu DX, Harrison GA, Mayer Bridwell AE, Prusa J, Chavez SM, Stallings CL. Annu Rev Pathol. 2021 Jan 24. doi: 10.1146/annurev-pathol-042120-032916.
- Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate. Gomez M, McCollum J, Wang H, Ordoubadi M, Jar C, Carrigy NB, Barona D, Tetreau I, Archer M, Gerhardt A, Press C, Fox CB, Kramer RM, Vehring R. Int J Pharm. 2021 Jan 25. doi: 10.1016/j.ijpharm.2020.120121. Epub 2020 Dec 2.
- Co-adsorption of synthetic Mincle agonists and antigen to silica nanoparticles for enhanced vaccine activity: A formulation approach to co-delivery. Abdelwahab WM, Riffey A, Buhl C, Johnson C, Ryter K, Evans JT, Burkhart DJ. Int J Pharm. 2021 Jan 25. doi: 10.1016/j.ijpharm.2020.120119. Epub 2020 Nov 27.
- The double-sided effects of Mycobacterium Bovis bacillus Calmette-Guerin vaccine. Li J, Zhan L, Qin C. NPJ Vaccines. 2021 Jan 25. doi: 10.1038/s41541-020-00278-0.
- Synthetic protein conjugate vaccines provide protection against Mycobacterium tuberculosis in mice. Hanna CC, Ashhurst AS, Quan D, Maxwell JWC, Britton WJ, Payne RJ. Proc Natl Acad Sci U S A. 2021 Jan 26. doi: 10.1073/pnas.2013730118
- Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease. Emery JC, Richards AS, Dale KD, McQuaid CF, White RG, Denholm JT, Houben RMGJ. Proc Biol Sci. 2021 Jan 27. doi: 10.1098/rspb.2020.1635. Epub 2021 Jan 20.
- CD8 T Cells Show Protection against Highly Pathogenic Simian Immunodeficiency Virus (SIV) after Vaccination with SIV Gene-Expressing BCG Prime and Vaccinia Virus/Sendai Virus Vector Boosts. Kato S, Shida H, Okamura T, Zhang X, Miura T, Mukai T, Inoue M, Shu T, Naruse TK, Kimura A, Yasutomi Y, Matsuo K. J Virol. 2021 Jan 28. doi: 10.1128/JVI.01718-20. Print 2021 Jan 28.